Cargando…

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE(®), Dompé) to submit evidence for the clinical and cost effectiveness of cenegermin for neurotrophic keratitis (NK). The Liverpool R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleeman, Nigel, Mahon, James, Nevitt, Sarah, Duarte, Rui, Boland, Angela, Kotas, Eleanor, Dundar, Yenal, McEntee, Joanne, Ahmad, Sajjad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861391/ https://www.ncbi.nlm.nih.gov/pubmed/31240690 http://dx.doi.org/10.1007/s41669-019-0138-z

Ejemplares similares

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2020)

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Bresnahan, Rebecca, et al.
Publicado: (2023)

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2020)

Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Lambe, Tosin, et al.
Publicado: (2018)

Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis
por: Sheha, Hosam, et al.
Publicado: (2019)

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2023)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Neurotrophic keratopathy: Clinical presentation and effects of cenegermin
por: Bu, Julia Bing, et al.
Publicado: (2022)

Resolution of a neurotrophic keratopathy associated hypopyon with cenegermin
por: Zambino, Nick, et al.
Publicado: (2021)

Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment
por: Epitropoulos, Alice T., et al.
Publicado: (2022)

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2018)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

A systematic review of health state utility values for thyroid cancer
por: Houten, Rachel, et al.
Publicado: (2020)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
por: Fleeman, Nigel, et al.
Publicado: (2019)

Role of Topical Cenegermin in Management of a Cornea Transplant in a Functionally Monocular Patient with Neurotrophic Keratitis and Facial Nerve Palsy: A Case Report
por: Pocobelli, Augusto, et al.
Publicado: (2020)

Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy
por: Arboleda, Alejandro, et al.
Publicado: (2022)

Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy
por: Pedrotti, Emilio, et al.
Publicado: (2022)

A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops
por: Fausto, Riccardo, et al.
Publicado: (2020)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

A Novel Treatment for Neurotrophic Corneal Ulcer Using Topical Cenegermin (OXERVATE™) Containing Recombinant Human Nerve Growth Factor
por: Ahuja, Abhimanyu S, et al.
Publicado: (2020)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation
por: Sacchetti, Marta, et al.
Publicado: (2021)

Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up
por: García-Delpech, Salvador, et al.
Publicado: (2022)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Diagnosis and management of neurotrophic keratitis
por: Sacchetti, Marta, et al.
Publicado: (2014)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

Insulin eye drops for neurotrophic keratitis
por: Moreker, Mayur R, et al.
Publicado: (2023)

Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation
por: Duarte, Rui, et al.
Publicado: (2019)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Neurotrophic keratitis: current challenges and future prospects
por: Versura, Piera, et al.
Publicado: (2018)

New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis
por: Koay, Su Yin, et al.
Publicado: (2022)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation
por: White, Craig A., et al.
Publicado: (2022)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Neurotrophic keratitis in a patient with dihydroxypyrimidine dehydrogenase deficiency
por: Kapoor, Bharat, et al.
Publicado: (2008)

Congenital Corneal Anesthesia and Neurotrophic Keratitis: Diagnosis and Management
por: Mantelli, Flavio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tp2d998l63l99dr3tdd42kqua0